Literature DB >> 27520561

p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth.

Yoshito Hayashi, Masahiko Tsujii, Takahiro Kodama, Tomofumi Akasaka, Jumpei Kondo, Hayato Hikita, Takuya Inoue, Yoshiki Tsujii, Akira Maekawa, Shunsuke Yoshii, Shinichiro Shinzaki, Kenji Watabe, Yasuhiko Tomita1, Masahiro Inoue2, Tomohide Tatsumi, Hideki Iijima, Tetsuo Takehara.   

Abstract

Cancer-associated fibroblasts (CAFs) create a microenvironment that contributes to tumor growth; however, the mechanism by which fibroblasts are phenotypically altered to CAFs remains unclear. Loss or mutation of the tumor suppressor p53 plays a crucial role in cancer progression. Herein, we analyzed how the p53 status of cancer cells affects fibroblasts by investigating the in vivo and in vitro effects of loss of p53 function in cancer cells on phenotypic changes in fibroblasts and subsequent tumor progression in human colon cancer cell lines containing wild-type p53 and in cells with a p53 functional deficiency. The growth of p53-deficient tumors was significantly enhanced in the presence of fibroblasts compared with that of p53-wild-type tumors or p53-deficient tumors without fibroblasts. p53-deficient cancer cells produced reactive oxygen species, which activated fibroblasts to mediate angiogenesis by secreting vascular endothelial growth factor (VEGF) both in vivo and in vitro Activated fibroblasts significantly contributed to tumor progression. Deletion of fibroblast-derived VEGF or treatment with N-acetylcysteine suppressed the growth of p53-deficient xenograft tumors. The growth effect of blocking VEGF secreted from cancer cells was equivalent regardless of p53 functional status. Human colon cancer tissues also showed a significant positive correlation between p53 cancer cell staining activated fibroblasts and microvessel density. These results reveal that fibroblasts were altered by exposure to p53-deficient epithelial cancer cells and contributed to tumor progression by promoting neovascularization. Thus, p53 acts as a modulator of the tumor microenvironment.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27520561     DOI: 10.1093/carcin/bgw085

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

1.  [Establishment of a rat model of dimethylbenzanthracene-induced vulvar squamous intraepithelial lesions].

Authors:  Yijin Fan; Huajun Tang; Yao Liu; Chengzhi Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  Stepwise Disease Progression Model of Subsolid Lung Adenocarcinoma with Cystic Airspaces.

Authors:  Woohyun Jung; Sukki Cho; Sungwon Yum; Jin-Haeng Chung; Kyung Won Lee; Kwhanmien Kim; Choon Taek Lee; Sanghoon Jheon
Journal:  Ann Surg Oncol       Date:  2020-05-03       Impact factor: 5.344

3.  Neural reprogramming via microRNAs: the new kid on the p53-deficient block.

Authors:  Deborah A Silverman; George A Calin; Jeffrey N Myers; Moran Amit
Journal:  Mol Cell Oncol       Date:  2020-05-07

Review 4.  Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance.

Authors:  Pritish Nilendu; Sachin C Sarode; Devashree Jahagirdar; Ishita Tandon; Shankargouda Patil; Gargi S Sarode; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cell Oncol (Dordr)       Date:  2018-07-19       Impact factor: 6.730

5.  The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.

Authors:  Hang Li; Zhen Wang; Mian Jiang; Run-Ping Fang; Hui Shi; Yu Shen; Xiao-Li Cai; Qian Liu; Kai Ye; Sai-Jun Fan; Wei-Ying Zhang; Li-Hong Ye
Journal:  Acta Pharmacol Sin       Date:  2018-09-04       Impact factor: 6.150

Review 6.  Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment.

Authors:  Luke Bu; Hideo Baba; Naoya Yoshida; Keisuke Miyake; Tadahito Yasuda; Tomoyuki Uchihara; Patrick Tan; Takatsugu Ishimoto
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

7.  Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review.

Authors:  Xiaofeng Li; Yueming He; Jinfeng Zhu; Hongxia Pang; Yongwei Lin; Jinyang Zheng
Journal:  Oncotarget       Date:  2018-09-14

8.  Zinc cooperates with p53 to inhibit the activity of mitochondrial aconitase through reactive oxygen species accumulation.

Authors:  Ya-Nan Xue; Ya-Nan Liu; Jing Su; Jiu-Ling Li; Yao Wu; Rui Guo; Bing-Bing Yu; Xiao-Yu Yan; Li-Chao Zhang; Lian-Kun Sun; Yang Li
Journal:  Cancer Med       Date:  2019-04-10       Impact factor: 4.452

9.  Exosomal microRNAs derived from colon cancer cells promote tumor progression by suppressing fibroblast TP53 expression.

Authors:  Shunsuke Yoshii; Yoshito Hayashi; Hideki Iijima; Takanori Inoue; Keiichi Kimura; Akihiko Sakatani; Kengo Nagai; Tetsuji Fujinaga; Satoshi Hiyama; Takahiro Kodama; Shinichiro Shinzaki; Yoshiki Tsujii; Kenji Watabe; Tetsuo Takehara
Journal:  Cancer Sci       Date:  2019-07-09       Impact factor: 6.716

10.  The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.

Authors:  Hongzhi Sun; Bo Zhang; Haijun Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.